IL257015B - Pharmaceutical combination of 2mdm inhibitor and 2bcl inhibitor - Google Patents

Pharmaceutical combination of 2mdm inhibitor and 2bcl inhibitor

Info

Publication number
IL257015B
IL257015B IL257015A IL25701518A IL257015B IL 257015 B IL257015 B IL 257015B IL 257015 A IL257015 A IL 257015A IL 25701518 A IL25701518 A IL 25701518A IL 257015 B IL257015 B IL 257015B
Authority
IL
Israel
Prior art keywords
inhibitor
pharmaceutical combination
bcl2
mdm2
mdm2 inhibitor
Prior art date
Application number
IL257015A
Other languages
English (en)
Hebrew (he)
Other versions
IL257015A (en
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56877086&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL257015(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL257015A publication Critical patent/IL257015A/en
Publication of IL257015B publication Critical patent/IL257015B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL257015A 2015-08-28 2018-01-18 Pharmaceutical combination of 2mdm inhibitor and 2bcl inhibitor IL257015B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562211080P 2015-08-28 2015-08-28
US201562243337P 2015-10-19 2015-10-19
US201562250574P 2015-11-04 2015-11-04
PCT/IB2016/055050 WO2017037579A1 (en) 2015-08-28 2016-08-24 Mdm2 inhibitors and combinations thereof

Publications (2)

Publication Number Publication Date
IL257015A IL257015A (en) 2018-03-29
IL257015B true IL257015B (en) 2022-02-01

Family

ID=56877086

Family Applications (2)

Application Number Title Priority Date Filing Date
IL257015A IL257015B (en) 2015-08-28 2018-01-18 Pharmaceutical combination of 2mdm inhibitor and 2bcl inhibitor
IL277239A IL277239B (en) 2015-08-28 2020-09-09 mdm2 inhibitors and combinations thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL277239A IL277239B (en) 2015-08-28 2020-09-09 mdm2 inhibitors and combinations thereof

Country Status (11)

Country Link
US (3) US20190060309A1 (enExample)
EP (2) EP4241850A3 (enExample)
JP (2) JP2018528206A (enExample)
KR (1) KR20180041677A (enExample)
CN (2) CN111821306A (enExample)
AU (2) AU2016314082B2 (enExample)
CA (1) CA2992221C (enExample)
ES (1) ES2962460T3 (enExample)
IL (2) IL257015B (enExample)
RU (2) RU2740091C2 (enExample)
WO (1) WO2017037579A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201613576A (en) 2014-06-26 2016-04-16 Novartis Ag Intermittent dosing of MDM2 inhibitor
AU2017345574A1 (en) 2016-10-19 2019-05-23 United States Government As Represented By The Department Of Veterans Affairs Compositions and methods for treating cancer
MX393780B (es) 2017-01-17 2025-03-24 Heparegenix Gmbh Inhibidores de proteina cinasa para promover la regeneracion hepatica o reducir o prevenir la muerte de hepatocitos
WO2018183762A1 (en) * 2017-03-29 2018-10-04 United States Government As Represented By The Department Of Veterans Affairs Methods and compositions for treating cancer
EP3600326B1 (en) * 2017-03-31 2023-01-25 Novartis AG Dose and regimen for an hdm2-p53 interaction inhibitor in hematological tumors
WO2019040511A1 (en) * 2017-08-22 2019-02-28 University Of Maryland Batimore DOUBLE INHIBITORS OF BCL-2 AND HDM2 FAMILIES BY CO-MIMETTISM OF ALPHA BH3 AND P53 PROPELLERS
JP2020536855A (ja) * 2017-09-26 2020-12-17 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア がんを治療するための組成物及び方法
US11406627B2 (en) 2017-10-12 2022-08-09 Novartis Ag Combinations of MDM2 inhibitors with inhibitors of ERK for treating cancers
AU2018395543A1 (en) * 2017-12-31 2020-07-23 Evergreen Biosciences Compositions for cryopreservation and methods of use thereof
JP7358372B2 (ja) * 2018-03-12 2023-10-10 羅欣薬業（上海）有限公司 イミダゾピロロン化合物及びその使用
US20210363254A1 (en) * 2018-03-20 2021-11-25 Novartis Ag Pharmaceutical combinations
EP3672594B1 (en) * 2018-07-31 2021-09-29 Ascentage Pharma (Suzhou) Co., Ltd. Combination product of bcl-2 inhibitor and mdm2 inhibitor and use thereof in the prevention and/or treatment of diseases
CN110772640B (zh) 2018-07-31 2023-02-03 苏州亚盛药业有限公司 Bcl-2抑制剂与利妥昔单抗和/或苯达莫司汀或与CHOP联合的协同抗肿瘤作用
EP3672595B1 (en) 2018-07-31 2021-07-21 Ascentage Pharma (Suzhou) Co., Ltd. Combination product of bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases
CN114522167A (zh) 2018-07-31 2022-05-24 苏州亚盛药业有限公司 Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途
CA3123356A1 (en) 2018-12-20 2020-06-25 Novartis Ag Combinations of a hdm2-p53 interaction inhibitor and a bcl2 inhibitor and their use for treating cancer
TW202118488A (zh) * 2019-07-26 2021-05-16 大陸商蘇州亞盛藥業有限公司 Mdm2抑制劑的藥物組合物及其在預防和/或治療疾病中的用途
US12343352B2 (en) 2019-12-03 2025-07-01 Ascentage Pharma (Suzhou) Co., Ltd. N-(phenylsulfonyl)benzamides and related compounds as Bcl-2 inhibitors
JP2023531375A (ja) * 2020-05-26 2023-07-24 ハンミ ファーム．カンパニー リミテッド がん治療における使用のためのベルバラフェニブ
CN115124533A (zh) * 2021-03-26 2022-09-30 浙江海正药业股份有限公司 四环类衍生物、其制备方法和其医药上的用途
JP2024157057A (ja) * 2021-06-29 2024-11-07 国立大学法人 東京大学 バレット食道の治療用組成物
CN117562907B (zh) * 2023-11-17 2025-08-22 广州医科大学 一种提升抗癌效果的可口服吉非替尼复合物及其制备方法与应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2416685C (en) 2000-07-19 2008-10-07 Warner-Lambert Company Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
DE60330227D1 (de) 2002-03-13 2010-01-07 Array Biopharma Inc N3-alkylierte benzimidazol-derivate als mek-hemmer
JP4163738B2 (ja) 2004-06-11 2008-10-08 日本たばこ産業株式会社 癌の治療用の５−アミノ−２，４，７−トリオキソ−３，４，７，８−テトラヒドロ−２Ｈ−ピリド’２，３−ｄ！ピリミジン誘導体及び関連化合物
US8299076B2 (en) 2005-05-18 2012-10-30 Array Biopharma Inc. Crystalline forms of 2-(2-flouro-4-iodophenylamino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxamide
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
UA104147C2 (uk) 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
EP2370566A1 (en) * 2008-12-03 2011-10-05 Università Degli Studi Di Torino Isogenic human cell lines comprising mutated cancer alleles and process using the cell lines
CU24130B1 (es) 2009-12-22 2015-09-29 Novartis Ag Isoquinolinonas y quinazolinonas sustituidas
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
US8859535B2 (en) * 2011-06-20 2014-10-14 Novartis Ag Hydroxy substituted isoquinolinone derivatives
WO2012178038A1 (en) * 2011-06-24 2012-12-27 The Broad Institute, Inc. Methods of treating cancer
US8815926B2 (en) * 2012-01-26 2014-08-26 Novartis Ag Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases
EP2752191A1 (en) * 2013-01-07 2014-07-09 Sanofi Compositions and methods using hdm2 antagonist and mek inhibitor
MX391859B (es) * 2013-11-11 2025-03-12 Amgen Inc Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres
TW201605450A (zh) * 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
WO2015095834A2 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Cancer treatments using erk1/2 and bcl-2 family inhibitors
RU2016129953A (ru) 2013-12-23 2018-01-30 Новартис Аг Фармацевтические комбинации

Also Published As

Publication number Publication date
RU2018110770A (ru) 2019-09-30
EP4241850A2 (en) 2023-09-13
RU2740091C2 (ru) 2021-01-11
CN111821306A (zh) 2020-10-27
RU2020142739A3 (enExample) 2021-05-20
RU2020142739A (ru) 2021-01-15
US20190060309A1 (en) 2019-02-28
AU2019204938B2 (en) 2020-07-16
EP3340989B1 (en) 2023-08-16
EP4241850A3 (en) 2023-11-08
IL277239A (en) 2020-10-29
CA2992221A1 (en) 2017-03-09
RU2018110770A3 (enExample) 2020-01-15
ES2962460T3 (es) 2024-03-19
US20230398115A1 (en) 2023-12-14
IL257015A (en) 2018-03-29
CN108348520A (zh) 2018-07-31
KR20180041677A (ko) 2018-04-24
AU2016314082B2 (en) 2019-07-25
AU2019204938A1 (en) 2019-07-25
IL277239B (en) 2022-04-01
CA2992221C (en) 2023-06-27
JP2018528206A (ja) 2018-09-27
JP2021042222A (ja) 2021-03-18
EP3340989A1 (en) 2018-07-04
AU2016314082A1 (en) 2018-02-08
WO2017037579A1 (en) 2017-03-09
US20210260059A1 (en) 2021-08-26

Similar Documents

Publication Publication Date Title
IL257015B (en) Pharmaceutical combination of 2mdm inhibitor and 2bcl inhibitor
IL265922A (en) tyk2 inhibitors and uses thereof
IL266109A (en) tyk2 inhibitors and uses thereof
IL267291A (en) Actonucleotidase inhibitors and methods of using them
IL251834A0 (en) Pharmaceutical compositions containing peptide variants and methods of using them
IL259796A (en) Aza-benzimidazole inhibitors of pad4
SI3700902T1 (sl) Inhibitorji trpc6
IL282482A (en) Variants of protoxin-II and methods of use
SG11201708034SA (en) Methods of administering glutaminase inhibitors
PT4335517T (pt) Administração e dosagem de diaminofenotiazinas
PT3380525T (pt) Formulações farmacêuticas e métodos que as utilizam
SI3532459T1 (sl) Zaviralci LSD1 in njihove medicinske uporabe
IL282508A (en) Variants of protoxin-II and methods of use
PT3319609T (pt) Composições e métodos de uso de combinações de fármacos antibacterianos
IL255530A (en) Efflux-pump inhibitors and therapeutic uses thereof
GB201413530D0 (en) Treatment and prevention of malaria
PT3397364T (pt) Elementos estruturados e métodos de utilização
PT3348547T (pt) Derivados de benzimidazole como inibidores de nav 1.7 (canal de sódio, controlado por tensão, tipo ix, subunidade alfa (scn9a)) para o tratamento de dor, disúria e esclerose múltipla
SMT201800640T1 (it) Irisina per la cura e la prevenzione dell'osteoporosi
PT3503885T (pt) Composição farmacêutica e métodos de utilização
IL252752A0 (en) Pharmaceutical preparations containing a combination of pyridazine and egfr inhibitor
IL252424A0 (en) Treatment of multiple sclerosis with a combination of laquinimod and a statin
PL3173075T3 (pl) Farmaceutyczny preparat złożony inhibitora ACE i diuretyku pętlowego
GB201612863D0 (en) Administration and dosage of diaminophenothiazines
AU2015902765A0 (en) Novel aminopeptidase inhibitors and methods of use